CML is a myeloproliferative disorder characterized by BCR-ABL oncoprotein with high tyrosine kinase activity, which promotes the proliferation and inhibits the apoptosis of cancer cells (63). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.